Taylor, Stephen

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Zuo, J., Dowell, A. C., Pearce, H., Verma, K., Long, H. M., Begum, J., Aiano, F., Amin-Chowdhury, Z., Hoschler, K., Brooks, T., et al. (2021) · Nature Immunology

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 392

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Reynolds, C. J., Pade, C., Gibbons, J. M., Butler, D. K., Otter, A. D., Menacho, K., Fontana, M., Smit, A., Sackville-West, J. E., Cutino-Moguel, T., et al. (2021) · Science

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 338

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett, J. R., Belij-Rammerstorfer, S., Dold, C., Ewer, K. J., Folegatti, P. M., Gilbride, C., Halkerston, R., Hill, J., Jenkin, D., Stockdale, L., et al. (2021) · Nature Medicine

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 315

Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England

Marsden, J., White, M., Annand, F., Burkinshaw, P., Carville, S., Eastwood, B., Kelleher, M., Knight, J., O'Connor, R., Tran, A., et al. (2019) · The Lancet Psychiatry

Opioid Use Disorder TreatmentPharmaceutical Practices and Patient Outcomes

Cited by 106

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

Marchevsky, N. G., Li, G., Aley, P., Costa Clemens, S. A., Barrett, J. R., Belij-Rammerstorfer, S., Bibi, S., Clutterbuck, E., Dold, C., Felle, S., et al. (2022) · eBioMedicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 17